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Abstract
Background: Because of the high global prevalence of latent TB infection (LTBI), a key challenge in endemic settings is
distinguishing patients with active TB from patients with overlapping clinical symptoms without active TB but with co-
existing LTBI. Current methods are insufficiently accurate. Plasma proteomic fingerprinting can resolve this difficulty by
providing a molecular snapshot defining disease state that can be used to develop point-of-care diagnostics.
Methods: Plasma and clinical data were obtained prospectively from patients attending community TB clinics in Peru and
from household contacts. Plasma was subjected to high-throughput proteomic profiling by mass spectrometry. Statistical
pattern recognition methods were used to define mass spectral patterns that distinguished patients with active TB from
symptomatic controls with or without LTBI.
Results: 156 patients with active TB and 110 symptomatic controls (patients with respiratory symptoms without active TB)
were investigated. Active TB patients were distinguishable from undifferentiated symptomatic controls with accuracy of
87% (sensitivity 84%, specificity 90%), from symptomatic controls with LTBI (accuracy of 87%, sensitivity 89%, specificity
82%) and from symptomatic controls without LTBI (accuracy 90%, sensitivity 90%, specificity 92%).
Conclusions: We show that active TB can be distinguished accurately from LTBI in symptomatic clinic attenders using
a plasma proteomic fingerprint. Translation of biomarkers derived from this study into a robust and affordable point-of-care
format will have significant implications for recognition and control of active TB in high prevalence settings.
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Introduction
Tuberculosis is the leading bacterial cause of death worldwide,
with an estimated 8.8 million new cases of active disease and 1.6
million deaths per year [1]. Much of the burden of disease lies in the
developing world, where annual incidence can reach 700 per
100,000 in certain regions [1].Newandunrecognised cases drive the
epidemic, with transmission usually occurring before the index case
is diagnosed. Multi-drug resistant cases and HIV co-infection
further complicate control efforts [2]. Pulmonary TB is the most
frequent clinical and transmissible manifestation of active disease.
Rapid diagnosis and treatment are critical in the prevention of
transmission.
The global burden of active TB occurs on a background of
quiescent or latent TB infection (LTBI), affecting one third of the
world’s population and a higher proportion of the population of
TB-endemic areas [3]. Respiratory and constitutional symptoms
overlapping with those of pulmonary TB are very common in
communities where TB is endemic [4]. In this scenario the
challenge is to distinguish symptomatic patients with active TB
from those with latent disease but whose presenting symptomatol-
ogy is attributable to some other infectious or inflammatory
process. In terms of rapid diagnosis, sputum microscopy will only
identify approximately 50% of patients with active pulmonary TB.
Conversely, while the interferon gamma release assays (IGRAs)
represent a major advance in the detection of latent TB, they
cannot distinguish active TB from symptomatic patients with
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latent infection in this context [5,6]. This overlap between LTBI,
active TB and non-specific clinical manifestations presents
a formidable obstacle to the rapid recognition of active TB and
the timely and appropriate targeting of anti-TB chemotherapy or
chemoprophylaxis. In practice this difficulty may give rise to 2
types of therapeutic error. In the first instance, erroneous diagnosis
of active TB in a symptomatic patient with LTBI may result in
inappropriate administration of full course TB treatment. Con-
versely, offering chemoprophylaxis to a patient with supposed
LTBI in whom active TB has not been recognized, will drive
emergence of drug resistance.
Pulmonary TB is characterised by granuloma formation,
caseation and ultimately cavitation, reflecting a complex interplay
between distinctive components of the innate and acquired
immune response and the pathogen [5]. Traditional serological
analysis of single circulating proteins is notoriously unreliable for
TB diagnosis [7]. In contrast, patterns of circulating proteins could
provide an accessible readout of pathophysiological status.
Discovery of such discriminatory biomarkers could open the way
for the development of new point-of-care tests based on a lateral
flow format such as dipsticks.
Proteomic analysis using Surface Enhanced Laser Desorption
Ionisation Time of Flight (SELDI-ToF) mass spectrometry is a high
throughput profiling methodology, which enables rapid compar-
ison of protein patterns from large numbers of patients. The
conceptual approach employed in the present study is termed
proteomic fingerprinting. It is based on the principle that
distinctive combinations of circulating proteins characterize
different disease states. This strategy has been applied to the
discovery of discriminatory proteomic patterns for a range of
diseases including cancer [8], vascular disease [9–11] and
infectious diseases [12–15]. Previously, we have demonstrated
that proteomic patterns based on such profiles can distinguish
active TB from healthy and symptomatic controls [12].
In the present study we hypothesized that plasma proteomic
differences would also distinguish patients with active TB from
those without active TB but with overlapping clinical symptoms,
irrespective of the co-existence of LTBI. Here we show that using
this approach, we can indeed discriminate accurately between
such patient groups.
Methods
Ethics Statement
All participants gave written informed consent and the research
was approved by internationally accredited ethics committees
including Universidad Peruana Cayetano Heredia (Lima, Peru)
and Imperial College London (London, United Kingdom). The
study involved adults from 15 years of age. Informed consent was
obtained from the next of kin, carers or guardians on the behalf of
the young adults involved in the study.
Study Participants
Participants were recruited over a period of two years from
adults over the age of 15 years attending 16 community TB clinics
serving a population of ,400,000 in the shantytown of Ventanilla
Figure 1. Patient recruitment. The figure illustrates the definitions of the patient subgroups and the routes by which they were recruited into the
study.
doi:10.1371/journal.pone.0038080.g001
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on the outskirts of Lima, Peru (Figure 1). All patients underwent
the local standardized clinical workup for TB. This included up to
4 consecutive sputum samples for microscopy and culture.
Participation in the study did not change patients’ routine clinical
management. The local incidence of TB in this population is
,130 per 100,000/year [16] and 95–97% of TB cases are HIV
negative [17]. We recruited patients with active TB and
individuals, termed symptomatic controls, presenting with re-
spiratory symptoms suspicious of TB in whom TB was sub-
sequently excluded.
Definition of Active TB, Latent TB and Symptomatic
Controls
Active TB cases were recruited on the basis of positive sputum
microscopy with subsequent confirmation by culture. Mycobacte-
rial culture was by automated liquid culture (BACTEC MGIT
960TM, BD) as well as the Microscopic Observation Drug
Susceptibility (MODS) assay which we have previously established
as a standard local laboratory protocol [18] and which has since
been adopted as the standard operating procedure by the national
TB programme in Peru. Symptomatic controls, those patients with
respiratory symptoms without active TB, were recruited if they
had a persistent cough and one or more of the following clinical
features: fever, weight loss, decreased appetite or haemoptysis.
Symptomatic controls had 1–4 sputum smears and cultures to
exclude active TB and were followed for 6 months to confirm that
cultures had not become positive or were re-classified accordingly.
Additional TB cases and symptomatic controls were identified
through tracing household contacts, from whom sputum smears
and cultures were obtained if symptomatic.
An IFN-c Release Assay (IGRA) (QuantiFERON-TB Gold In-
TubeH) was performed on all participants. Latent TB was defined
as a positive QuantiFERONH assay in the absence of clinical or
microbiological evidence for active TB.
The Tuberculin Skin Test (TST) has limited value in the
diagnosis of active TB and it was not carried out in our active TB
patient group. We carried TST in the symptomatic controls
group.
Sample Collection
A 4 ml blood sample was obtained from each participant in an
EDTA blood collection tube for subsequent plasma separation.
Three additional aliquots were obtained at the same time for the
QuantiFERONH-TB Gold in tube assay. Plasma was obtained
before initiating TB treatment; otherwise plasma was taken within
1–2 days of treatment. Blood samples were transferred to the
central laboratory on ice. Plasma was separated (3500 rpm, 10
minutes), aliquoted and frozen at 270uC at 6 hours following
collection.
QuantiFERONH -TB Gold in Tube Assay
This was performed according the manufacturer’s instructions
(Cellestis Plc, Sydney, Australia).
Plasma Proteomic Profiling
Plasma was profiled using Surface Enhanced Laser Desorption/
Ionisation-Time Of Flight (SELDI-TOF) mass spectrometry. All
samples underwent a single freeze-thaw cycle prior to analysis.
Samples were coded, blinded and randomised before application
onto weak cation exchange (CM10) ProteinChipH arrays (Bio-
Rad) in duplicate, as previously described [12]. Each ProteinCh-
ipH included 1 quality control standard derived from a single
healthy individual, placed at random. Liquid handling steps were
automated using a Biomek 3000 Laboratory Automation Work-
station (Beckman Coulter) and a 96 well BioprocessorH (Bio-Rad).
Mass spectra were generated on an automated System 4000
Bio-Rad ProteinChipH reader. Mass spectra data were collected
and analysed using the ProteinChipH Data Manager Client 3.5
software (BioRad Inc.). Spectra were generated at both high
(3,000 nJ) and low (1,600 nJ) laser energies with mass focus set to
40,000 Da and 6,000 Da respectively. Spectra were normalised by
total ion current starting with a minimum mass/charge (m/z) of
2,500. Spectra with normalisation factor outside mean 62
standard deviations were removed. The remaining spectra were
re-normalised by total ion current. Spectral peaks corresponding
to mass/charge (m/z) clusters were detected and clustered using
the ProteinChipH Data Manager Client 3.5 software (BioRad Inc.)
by auto-detecting peaks to clusters in two steps. For the first step
a signal to noise ratio of 5 and valley depth of 3 were used, with
a minimum peak threshold of 20% of all spectra. For the second
step a signal to noise ratio of 3 and valley depth of 1 were chosen.
The cluster window was set at 1.0 peak width and expression
difference mapping performed over m/z range of 2,500 to
200,000.
Table 1. Characteristics of study patients.
Active TB Symptomatic Controls
Latent No Latent All
N (%) 151 53 (48) 44 (40) 110**
Age Years
Median (IQR)
28.5 (15.5) 37 (27.5) 29 (20.5) 32 (23)
Sex Ratio
Female:Male
68:83 34:19 30:14 73:37
Smear***
Positive 139 0 0 0
Negative 7 53 44 110**
Culture‘
Positive 139 0 0 0
Negative 8 53 44 110**
History BCG
vaccination (%)
121 (80) 44 (83) 39 (89) 94 (86)
Previous history
TB (%)
34 (22) 11 (21) 6 (14) 20 (18)
Tuberculin Skin
Test (%){
Positive * 33 (62) 13 (30) 46 (42)
Negative * 11 (21) 25 (57) 36 (33)
Cough.7 Days (%) 118 (78) 24 (45) 22 (50) 53 (48)
Haemoptysis (%) 72 (48) 15 (28) 11 (25) 28 (26)
Fever.7 Days (%) 40 (26) 4 (8) 1 (2) 6 (6)
BMI Mean (sd) 21.6 (3) 25 (4.8) 23.5 (4.3) 24.1 (4.7)
Night-sweats.
10 Days (%)
53 (35) 7 (13) 4 (9) 14 (13)
Weight-loss.
4 Weeks (%)
69 (46) 9 (17) 5 (11) 19 (17)
TST-Tuberculin Skin Test. BMI-Body Mass Index. *TST was not performed in
patients with active TB. **The QuantiferonGold test was indeterminate or
unavailable on 13 symptomatic control patients. ***Smear results from 5
patients were unavailable. ‘Culture results from 4 patients were unavailable.
{TST results were unavailable for 28 control patients.
doi:10.1371/journal.pone.0038080.t001
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Instrument calibration was performed using All-in-1 Peptide
and Protein calibrants (Bio-Rad). Reproducibility was determined
by measuring the inter-ProteinChipH coefficient of variation (CV)
for the quality control spectra, based on all peaks in the spectrum
with intensity .1 mA. Overall interchip CV for the quality control
sample was 20%, consistent with similar studies.
Plasma Anion Exchange Fractionation
Because highly abundant proteins/peptides suppress signal from
lower abundance analytes in complex mixtures such as crude
plasma, SELDI-ToF spectra were generated from both crude and
pre-fractionated plasma to determinewhether accessing the ‘deeper’
proteome yielded additional diagnostic information. Anion-ex-
Figure 2. Heat map of crude plasma spectral data from active TB and symptomatic controls. Each vertical line represents an active TB
patient or symptomatic control. Each horizontal line represents a protein with a particular molecular mass. Areas where a protein is present in high
abundance are seen in red and low abundance in green.
doi:10.1371/journal.pone.0038080.g002
Figure 3. Mass spectra comparing 11.5 kDa and 5.8 kDa peaks in active TB and symptomatic controls. Mass spectra from 5 kDa to
12 kDa of four active TB and four symptomatic controls individuals. Intensity in mA is plotted in y-axis.
doi:10.1371/journal.pone.0038080.g003
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change fractionation was carried out using the ProteinChipH Serum
Fractionation Kit (Bio-Rad) according to the manufacturer’s
instructions with a Biomek 3000 Laboratory Automation Worksta-
tion. Six fractions were obtained from each sample eluting at
pH 9.0, pH 7.0, pH 5.0, pH 4.0, pH 3.0 and organic phase.
Data Analysis
To visualize the covariance within the mass spectral profiles we
used Principal Component Analysis (PCA). PCA encapsulates the
covariance within a set of variables by extracting a ranked set of
independent factors or principal components. The first 3
components encompass a high proportion (,95%) of the
informational content of a multivariate dataset. We plotted each
patient with respect to the first 3 components, in 3-dimensional
space, color-coding according to patient group.
Although PCA is useful for visualizing data it cannot provide
a classification rule for discriminating between patient categories.
To find such discriminatory proteomic patterns, we adopted
a supervised learning approach in which patient categories are
used to train an algorithm to derive a classification rule. We used
a Support Vector Machine (SVM) method [19]. Briefly, we used
10-fold cross validation to select parameters for the SVM. For the
final model parameters, we selected those that gave the overall
highest accuracy across the whole 10 fold cross validation. We next
selected a subset of the most relevant mass clusters using the
Recursive Feature Elimination (RFE) algorithm [20] which ranks
variables based on their contribution to the classifier. To obtain
accuracy estimates for the classifier, we took 1000 random re-
samplings of the original data, using 90% for training and 10% for
testing. We selected as a final classifier the one that produced the
highest accuracy while requiring the smallest number of m/z
clusters. Results were expressed as sensitivity, specificity and
accuracy (proportion of correct classifications) and as Receiver
Operator Characteristic (ROC) curves. We assessed the different
performances of classifiers derived from crude and pre-fraction-
ated plasma by comparing mean values for sensitivity, specificity
and accuracy using unpaired 2-tailed t tests. Comparisons of
categorical data were by Fisher’s exact test.
Results
Characteristics of study patients
151 patients with active TB and 110 symptomatic controls were
recruited (Figure 1). Of patients with active TB, 139 were both
smear and culture positive, with the remainder either smear or
culture positive. 48% of symptomatic controls had LTBI on the
basis of a positive QuantiferonGold assay. Symptomatic controls
had clinical features overlapping those of active TB patients,
including cough, haemoptysis, fever, night sweats and weight loss,
although symptom duration was generally longer among TB
patients. Similar proportions of TB patients and symptomatic
controls reported a previous history of TB (22% vs. 18%). The
proportion reporting a history of TB was higher among controls
with LTBI than among those without but did not reach statistical
significance. Patients with active TB had lower BMIs at the time of
recruitment compared with symptomatic controls (21.6 vs.
24.1 p,0.001). As expected, a higher proportion of patients with
LTBI based on a positive IGRA had positive TSTs (.10 mm)
compared with those without LTBI (62% vs. 30%, p,0.001).
There was a higher proportion of female patients among the
symptomatic controls than among the TB group. The effects of
this potential bias are discussed below. Other key clinical features
of the participant groups are given in Table 1.
Discrimination of Active from Latent Tuberculosis in
Symptomatic Patients
We plotted crude plasma global protein expression profiles in
a heat map (Figure 2) that shows spectra patterns from active TB
patients and unhealthy controls. The most striking area of up-
regulation in TB patients is seen in the 11 kDa region where
a series of protein peaks are seen in red amongst TB patients
(Figure 2). A parallel area of up-regulation is seen at 5 kDa and
a third smaller area seen at the 21 kDa region (Figure 2).
Inspecting in more detail the spectra in the 5.8 and 11.5 kDa
regions (Figure 3) reveals a complex of peaks at both these regions,
which is more abundant in patients with active TB.
Figure 4. Clustering of patients with active TB and symptomatic controls with or without latent TB using principal component
analysis. a. Crude plasma spectra; b. Fractionated plasma spectra. Each sphere represents an individual patient spectrum plotted in 3D space
defined by the first three principal components. Purple = active TB; Blue = symptomatic controls with latent TB; Green= symptomatic controls without
latent TB.
doi:10.1371/journal.pone.0038080.g004
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We assessed overall separability of patient groups by PCA of
mass spectra from crude and pre-fractionated plasma (Figure 4 a–
b). In figure 4, each patient sample is plotted in a 3-dimensional
space defined by the first 3 principal components. The spectra
from patients with active TB (purple spheres) cluster relatively
tightly together and are well separated from symptomatic control
patients (blue and green spheres) regardless of LTBI. This analysis,
however, does not clearly separate symptomatic controls with or
without LTBI (blue and green spheres, respectively).
The SVM classifiers distinguished active TB from both classes
of symptomatic controls. The ROC curves in Figure 5 (a–f)
summarize the performance of the classifiers, in terms of the trade-
off between sensitivity and specificity, for each of the different
comparisons. In each case, the area under the curve (AUC)
exceeded 0.9, irrespective of whether crude or pre-fractionated
plasma was analyzed, indicating a high level of discrimination.
Tables 2 and 3 and Tables S1 and S2 summarize the performance
of the classifiers in discriminating active from latent tuberculosis in
symptomatic patients using the number of selected relevant m/z
clusters (Table 3 in brackets). It was possible to distinguish patients
with active TB from undifferentiated symptomatic controls with
partially overlapping respiratory and constitutional symptoms with
an overall accuracy of 85% using crude spectra with 98 relevant
m/z clusters (Table 2, Table 3, Figure 5a). A higher specificity for
active TB (90% vs. 84%, p,0.001) was achieved using pre-
fractionated plasma with a total of 54 relevant m/z clusters
(Table 2, Table 3, Figure 5b). Notably, these levels of discrimi-
nation were achieved despite nearly half of the symptomatic
controls having LTBI (Table 1).
To further investigate the influence of background LTBI on
classifier performance, separate comparisons were made between
active TB and symptomatic controls either with or without LTBI.
In both comparisons, active TB could be distinguished from
symptomatic controls with overall classifier accuracies of at least
87% (Table 2, Table 3, Figure 5 c–f, Tables S1 and 2). Active TB
was readily distinguishable from symptomatic controls without
LTBI using both crude and fractionated plasma, with overall
accuracies, sensitivities and specificities of at least 90% (Table 2,
Table 3, Figure 5 e,f and Table S1 and S2). The main influence of
LTBI among the symptomatic controls was to reduce classifier
specificity, reflected in a higher proportion of false positives.
Strikingly, plasma pre-fractionation improved specificity from
75% to 82% only using four m/z clusters (Table 2, Table 3,
Figure 5 c,d, p,0.001).
To address the issue of the gender bias in cases and controls we
reanalysed the data to determine whether a classifier based on the
proteomic profile could reliably discriminate males from females.
This was found not to be the case, suggesting that gender is not
a major confounder in our analysis. As a further test, a new
classifier was trained on male patients alone, to discriminate active
TB from symptomatic controls. When we applied the trained
classifier to the female subjects, this classifier was nevertheless still
capable of classifying TB to an accuracy of approximately 80%.
We also confirmed the presence of differential expression of the
Serum Amyloid A (SAA, 11.5–11.8 kDa) and transthyretin (13.7–
13.8 kDa ) peak complexes which emerged in our previous study
[12] as important informative markers for active TB. SAA was
identified by specific immunodepletion (data not shown).
Discussion
In this study we have shown that a distinctive pattern of plasma
proteins distinguishes patients with active TB from non-TB
patients with overlapping clinical features, even in the presence
of LTBI. This both reinforces and substantially extends our
previous findings where we first showed that proteomic patterns
could be used as a diagnostic approach for active TB [12]. We
have now shown that the proteomic pattern does not merely
reflect the presence of TB infection per se. Rather, it can be used to
identify active TB even in a highly TB-endemic setting with high
prevalence of both respiratory symptoms and background LTBI.
Figure 5. Diagnostic performance of proteomic fingerprints. The diagnostic performance of classifiers based on proteomic fingerprints are
shown using Receiver Operator Characteristic Curves (ROC). (a,b) active TB vs. all symptomatic controls using crude or pre-fractionated plasma
respectively; (c,d) active TB vs. symptomatic controls with latent TB using crude or pre-fractionated plasma respectively; (e,f) active TB vs.
symptomatic controls without latent TB using crude or pre-fractionated plasma respectively. The ROCs are derived from 1000 random train/test re-
samplings of the data. Error bars show standard deviations. The Area Under the Curve (AUC) is shown in the centre of each plot.
doi:10.1371/journal.pone.0038080.g005
Table 2. Discrimination of active from latent tuberculosis in symptomatic patients.
Accuracy
(%6sd)
Sensitivity
(%6sd)
Specificity
(%6sd) AUC6sd
Crude Plasma: Clinical Group (N)
ActiveTB (151) vs. All Symptomatic Controls (110) 8567 8569 84610* 0.9160.06
ActiveTB (151) vs. Symptomatic LATENT Controls (53) 8867 9267 75619** 0.9160.08
ActiveTB (151) vs. Symptomatic NOLATENT Controls (44) 9565 9665 91614 0.9960.02
Pre-fractionated Plasma: Clinical Group (N)
ActiveTB (99) vs. All Symptomatic Controls (100) 8767 84612 90610* 0.9360.06
ActiveTB (99) vs. Symptomatic LATENT Controls (49) 8769 89610 82618** 0.9260.08
ActiveTB (90) vs. Symptomatic NOLATENT Controls (40) 9068 90610 92613 0.9560.06
The classifier performance is expressed as accuracy, sensitivity and specificity as percentages +/2standard deviations obtained by 1000 train/test randomizations of the
data. (AUC) = Area Under Curve in ROC analysis. *Pre-fractionated vs. Crude Plasma p,0.001. **Pre-fractionated vs. Crude Plasma p,0.001. For all other comparison
there are not significant differences between the performance of crude and pre-fractionated plasma.
doi:10.1371/journal.pone.0038080.t002
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The ability to discriminate rapidly in a symptomatic patient
between active TB and non-tuberculous disease has profound
implications for both individual clinical management and TB
control programs [21]. For example, current diagnostic limitations
frequently result in many patients in resource-poor settings being
treated empirically for community acquired pneumonia before
eventual diagnosis of active TB. This may lead to on-going
transmission during the interval preceding diagnosis as well as
greater individual morbidity. The alternative strategy of empirical
anti-TB chemotherapy is sometimes employed, but cost, toxicity
and logistics often preclude this. Adjuncts to conventional
microbiology for diagnosis of active TB in widespread use include
the TST and IGRAs. The use of TSTs in the diagnosis of active TB
in high prevalence settings is greatly limited by its poor specificity
for active TB as reactivity is also seen in LTBI, previous BCG
vaccination and exposure to environmental mycobacteria. Nor has
the recent introduction of IGRAs into clinical practice resolved this
key diagnostic issue. This is because of their inability to distinguish
active TB from LTBI [6] and frequent false negative results in
acute active TB [22], limitations which are especially problematic
in high prevalence settings [23]. Thus a diagnostic that overcomes
these limitations is urgently required and would be a major advance
in the management of the global TB pandemic. Recently it has
been reported that a TNF-alpha+ TB-specific CD4+response can
be used to differentiate latent infection from active TB but the
sensitivity was just 67% [24]. Moreover, that study relied on
polychromatic flow cytometry limiting the feasibility of being
translated in high prevalence settings. In contrast, our approach
provides improved accuracy, 87%, by detecting relevant protein
biomarkers in plasma. Despite the discovery-phase of our approach
using sophisticated proteomic methodologies, the identification of
relevant plasma proteins leads to a clear translational path for
antibody-based point-of-care devices that can be used to measure
these plasma proteins in the future.
There is increasing interest in the identification of novel
biomarkers for TB - in the contexts of diagnosis, treatment
response monitoring, prediction of relapse or re-activation and as
surrogates for vaccine protection. Most studies have focused on
individual markers such as secreted M. tuberculosis antigens,
serological responses, microbiological indices and host inflamma-
tory markers, with mixed results [7,25]. There is growing
recognition of the advantages of using combinatorial biomarker
panels or ‘omics’-based methods to achieve sufficient levels of
accuracy [25]. However, relatively few studies have utilized such
strategies.
Proteomic fingerprinting for biomarker discovery has been
applied in the past decade to a variety of disease states, particularly
in the sphere of cancer diagnostics [26,27]. The power of this
approach is reflected by the recent granting of FDA approval of
a novel blood test derived from a SELDI-based fingerprinting
method, for distinguishing malignant from benign ovarian
tumours [27,28]. In many infectious diseases, there are clinically
important distinctions to be made between different manifestations
associated with the same underlying pathogen. For example,
distinguishing colonization or latent disease from active infection
has obvious clinical and therapeutic implications. TB is a clear
case in point. Proteomic fingerprinting has enormous potential for
defining and distinguishing these disease states but has only
recently received attention in this area [12–14,29–31]. Because the
circulation samples deep tissues throughout the body, local
proteomic changes in organs such as the lungs can be reflected
in the plasma proteome. Moreover, host modulation by the
pathogen is likely to generate changing patterns of protein
expression associated with different clinical manifestations. Thus
the plasma proteomic response is a plausible index of disease state.
Proteomic patterns are highly dynamic and it may be possible to
define those that reflect stages in progression from latency to active
disease. However, the complexity of the plasma proteome with its
enormous dynamic range of solute concentrations means that
detection of informative lower abundance proteins is particularly
challenging. It is possible that differences between active TB and
LTBI in symptomatic patients are reflected better by such lower
abundance proteins not easily detectable in crude plasma. This
may explain the higher specificity for active TB obtained from pre-
fractionated as compared to the crude plasma spectra.
The gold standards used for defining patient groups in this study
are notoriously imperfect. For example, while active TB was
defined by positive microbiology, it is possible that some patients
designated symptomatic controls may actually have had smear and
culture negative TB. This might have resulted in an underestimate
of the specificity of our diagnostic pattern for active TB, although
our 6 months follow-up and appropriate re-labelling should have
identified most of these. The lack of an adequate gold standard for
defining LTBI must also be considered. While IGRAs show
greater specificity than TSTs, sensitivity may be compromised
especially in early active TB [22]. Thus some patients with
unrecognized smear and culture negative TB may have been
mislabeled as symptomatic controls without LTBI.
We did not perform routine HIV testing in our patient cohort
and it is possible that over-representation of HIV seropositivity in
our active TB group may have had a confounding effect. We
believe this is unlikely in view of the low prevalence of HIV co-
infection among TB patients in Peru (,5%) found in previous
studies [17]. Important areas of future study will be to establish the
applicability of this approach in the contexts of TB-HIV co-
infection and smear-negative TB.
Our present findings confirm the utility of defining the host
proteomic response in distinguishing clinically overlapping patient
Table 3. Number of mass/charge (m/z) clusters derived from crude and pre-fractionated plasma.
Crude Plasma Pre-fractionated Plasma
F1 F2 F3 F4 F5 F6
ActiveTB vs. All Symptomatic Controls 271 (98) 102 (10) 72 (8) 93 (4) 85 (8) 75 (12) 96 (12)
ActiveTB vs. Symptomatic LATENT Controls 271 (33) 102 (0) 72 (0) 93 (0) 85 (0) 75 (4) 96 (0)
ActiveTB vs. Symptomatic NOLATENT Controls 271 (57) 102 (16) 72 (0) 93 (8) 85 (0) 75 (8) 96 (5)
Total number of mass/charge (m/z) clusters obtained from SELDI-ToF profiling of crude and pre-fractionated plasma. In brackets number of relevant discriminatory m/z
clusters selected by the RFE algorithm. F1 = fraction 1 at pH 9; F2 = fraction 2 at pH 7; F3 = fraction 3 at pH 5; F4 = fraction 4 at pH 4; F5 = fraction 5 at pH 3; F6 = fraction
6 organic phase.
doi:10.1371/journal.pone.0038080.t003
Discriminating Active from Latent Tuberculosis
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e38080
groups in a TB clinic setting. Moreover, this study shows that
active TB can be identified by a blood test in a population of
community TB clinic attenders, on a background of non-TB
attributable symptoms, despite the coexistence of LTBI. Ultimate-
ly, a significant impact on control of TB in high prevalence settings
will depend on the ability to translate these findings into a robust,
affordable point-of-care format. Incorporation of a panel of
biomarkers derived from this study into a lateral flow device or
similar platform is the logical next step. Finally, the utility of
defining proteomic patterns in TB may extend beyond diagnostics
to provide new methods for monitoring treatment response and
disease stage.
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